ICAD Displaying its Radiation System for Residual Breast Cancer at Conference

ICAD Displaying its Radiation System for Residual Breast Cancer at Conference
ICAD is showcasing its Xoft radiation system for treating post-surgery residual breast cancer at the American Society of Breast Surgeons annual meeting in Las Vegas. Two leading breast-cancer surgeons agreed to be at the Xoft booth during the conference, which started April 26 and runs through April 30, to explain how they use the non-radioactive system to treat early-stage breast cancer. Patients usually receive radiation therapy five days a week for five to six weeks. The Xoft system delivers a concentrated dose of radiation directly into the tumor during surgery, an approach that doctors call interoperative radiation therapy, or IORT. In addition to breast tumors, it is used to treat a number of other cancers. Radiation during surgery helps kill any microscopic bits of cancer that could remain after a tumor has been removed. It also reduces subsequent radiation treatments. “With the growing worldwide adoption of the Xoft System, an increasing number of clinicians are recognizing that this revolutionary technology offers a safe and effective treatment option for patients with early-stage breast cancer who meet specific selection criteria,” Ken Ferry, CEO of iCAD, said in a press release. “We are pleased to highlight the unique clinical experiences of two expert Xoft IORT breast surgeons at this year’s ASBrS meeting and share in their commitment to making innovative, clinically-proven treatment options like IORT available to their patients.” The U.S. Federal Drug Administration has app
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.